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doi:10.1Objective: Diagnosis of infection in patients receiving extracorporeal membrane oxygenation is challenging in
clinical practice but represents a crucial aspect of the upgrading of therapeutic options. The aim of this study was
to analyze the role of C-reactive protein and procalcitonin in the diagnosis of infection in patients requiring ex-
tracorporeal membrane oxygenation and to assess the difference between venovenous and venoarterial extracor-
poreal membrane oxygenation settings.
Methods:A case-control study was performed on 27 patients. Serum values of procalcitonin and C-reactive pro-
tein were analyzed according to the presence of infection.
Results: Forty-eight percent of patients had infection. Gram-negative bacteria were the predominant patho-
gens, and Candida albicans was the most frequent isolated microorganism. Procalcitonin had an area under
the curve of 0.681 (P ¼ .0062) for the diagnosis of infection in the venoarterial extracorporeal membrane
oxygenation group but failed to discriminate infection in the venovenous extracorporeal membrane oxygen-
ation group (P ¼ .14). The area under the curve of C-reactive protein was 0.707 (P< .001) in all patients
receiving extracorporeal membrane oxygenation. In patients receiving venoarterial extracorporeal membrane
oxygenation, procalcitonin had good accuracy with 1.89 ng/mL as the cutoff (sensitivity ¼ 87.8%,
specificity ¼ 50%) and C-reactive protein with 97.70 mg/L as the cutoff (sensitivity ¼ 85.3%,
specificity ¼ 41.6%). The procalcitonin and C-reactive protein combined assay had a sensitivity of
87.2% and specificity of 25.9%. Four variables were identified as statistically significant predictors of infec-
tion: procalcitonin and C-reactive protein combined assay (odds ratio, 1.184; P< .001), age (odds ratio,
0.980; P<.001), presence of infection before extracorporeal membrane oxygenation implantation (odds ra-
tio, 1.782; P< .001), and duration of extracorporeal membrane oxygenation support (odds ratio, 1.056;
P< .001).
Conclusions: Traditional and emerging inflammatory biomarkers, especially if compounded in the procalcitonin
and C-reactive protein combined assay, can aid in the diagnosis of infection in patients undergoing venoarterial
extracorporeal membrane oxygenation. (J Thorac Cardiovasc Surg 2012;143:1411-6)T
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Extracorporeal membrane oxygenation (ECMO) repre-
sents an effective tool for the treatment of heart and lung
failure. Nevertheless, clinicians may encounter many hard-
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Eoption. One of the most problematic challenges is to define
the presence and onset of infection and sepsis, because
these critically ill patients invariably present clinical signs
of systemic inflammatory response.1 In such patients, the
systemic inflammatory response syndrome (SIRS) is due
to both the underlying acute disease and the host response
to the presence of the extracorporeal circuit itself. The is-
sue is critical because mortality in sepsis is high and early
therapeutic intervention can improve prognosis.2 On the
other hand, broad use of antibiotics in all patients with
SIRS may lead to a prevalence of resistant strains with in-
creasing toxicity and costs. Moreover, when ECMO is
used as a bridge to other potential therapeutic options, in-
cluding organ transplant and long-term assist device im-
plantation, the presence of infection is to be rigorously
established to evaluate whether patients’ eligibility criteria
are met.
This study analyzes the role of C-reactive protein (CRP)
and procalcitonin (PCT) in the diagnosis of bacterial and
fungal infection in critically ill patients requiring ECMO,
and a new diagnostic test for clinical practice is presented.diovascular Surgery c Volume 143, Number 6 1411
Abbreviations and Acronyms
ARDS ¼ acute respiratory distress syndrome
CI ¼ confidence interval
CRP ¼ C-reactive protein
ECMO ¼ extracorporeal membrane oxygenation
ICU ¼ intensive care unit
NPV ¼ negative predictive value
OR ¼ odds ratio
PCT ¼ procalcitonin
PPV ¼ positive predictive value
ROC ¼ receiver operating characteristic
SE ¼ sensitivity
SIRS ¼ systemic inflammatory response
syndrome
SP ¼ specificity
VA ¼ venoarterial
VV ¼ venovenous
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SMATERIALS AND METHODS
Setting and Study Population
After ethical committee approval, we carried out an observational study
on 27 adult patients who were treated with venovenous (VV) ECMO or ve-
noarterial (VA) ECMObetween November 2009 and January 2011, and ad-
mitted to the cardiovascular intensive care unit (ICU) of Istituto Scientifico
San Raffaele.
Eleven patients with severe acute respiratory distress syndrome (ARDS)
were treated with VV ECMO, and 16 patients with refractory cardiogenic
shock were treated with VA ECMO. Among patients receiving VV ECMO,
7 had confirmed or strongly suspected ARDS due to H1N1 influenza A in-
fection. The other 4 patients treated with VV ECMO had ARDS after poly-
trauma, cardiogenic shock, pneumonia with negative microbiological tests,
and pancreatic surgery. None of the patients receiving VA ECMO had ev-
idence of infection at the time of cannulation, except 1 patient with H1N1
myocarditis with positive pharyngeal swab. Thirteen of 27 patients had in-
fection, and 14 patients were part of the control group.
Clinical Management
The ECMO circuit setup consisted of a centrifugal pump and a heparin-
coated polymethylpentene oxygenator. Two patients received a circuit
without an oxygenator for isolated refractory acute heart failure with pre-
served pulmonary function. Because all the other components of the circuit
and clinical management were identical to those of the patients receiving
VA ECMO, these 2 patients were included in the VA ECMO group.
All patients were intubated during ECMO support, except 1 patient with
non–H1N1-related pneumonia who received VV ECMO after failure of
noninvasive ventilation. Baseline monitoring consisted of invasive pressure
monitoring, pulse oximetry, continuous electrocardiography, urine output,
and central venous pressure. Chest radiogram and transesophageal echo-
cardiographic evaluations were performed and repeated as needed. Ther-
modilution cardiac output measurements were done. Arterial blood gas
analysis was performed every hour. Evaluation of hematocrit, white blood
cell count, coagulative profile (activated clotting time, prothrombin time,
partial thromboplastin time, antithrombin, free hemoglobin, fibrinogen,
D-dimer, and C protein), and electrolytes were performed every 6 hours
or when deemed necessary. Continuous clinical monitoring for bleeding
was performed, and laboratory measurement was requested more fre-
quently if necessary. Daily evaluation of cardiac enzymes, hepatic en-
zymes, and creatinine was performed. Blood gas analysis from radial1412 The Journal of Thoracic and Cardiovascular Surartery, pre-oxygenator blood, and post-oxygenator blood was performed
daily. Continuous evaluation of the ECMO circuit, clotting formation,
and pressure difference was performed.
Hemolysis was monitored by daily measurement of serum concentra-
tions of lactate dehydrogenase and free hemoglobin. Hemolysis was diag-
nosed in the presence of lactate dehydrogenase serum levels greater than
1000 U/L and a serum free hemoglobin level greater than 40mg/L in 2 con-
secutive samples within 24 hours. In addition to these elements, a reduction
of hemoglobin serum values and eventually hematuria strongly supported
the diagnosis.
Anticoagulation was achieved by intravenous continuous infusion of
unfractionated heparin titrated to maintain an activated partial thrombo-
plastin time between 45 and 50 seconds. In case of heparin-induced throm-
bocytopenia, unfractionated heparin was discontinued and intravenous
bivalirudin infusion was started.
In addition to anticoagulation therapy, standard intravenous therapy in-
cluded gastric prophylaxis with histamine H2-receptor antagonists, antibi-
otic prophylaxis with cefazolin for the first 48 hours after cannulation
procedure, hydration, and diuretics. Patients with defined or suspected
H1N1 influenza A infection received antiviral therapy with oseltamivir
150 mg twice per day and broad-spectrum antibiotics.
Infection Monitoring and Diagnosis
For infection surveillance and management, we followed international
guideline recommendations.3 Infection diagnosis followed Centers for Dis-
ease Control and Prevention criteria for specific types of infections in the
acute care setting. The Centers for Disease Control and Prevention devel-
oped criteria for the diagnosis of 48 specific sites or types of infection and
grouped them into 13 major site categories. The diagnosis is based on the
presence of a combination of criteria (including clinical signs and symp-
toms, vital signs, microbiological investigations, and clinical evidence)
that are different and clearly stated according to the different types of
infection.4
Three sets of blood cultures, deep tracheal aspirate or bronchoalveolar
lavage, and urine samples were sent periodically to the laboratory for mi-
crobiological examination. Whenever an intravascular device was changed
or removed, the tip was sent for microbiological investigation. Three sets of
blood cultures were obtained in case of fever (38C) or increase in white
blood cell count. A deep tracheal aspirate and eventually a bronchoalveolar
lavage were obtained whenever respiratory infection was suspected, such
as in changes on chest radiography or evidence of worsening in respiratory
performance.
A urinary sample was sent for cultural examination whenever standard
monitoring cultural examinations were performed and whenever deemed
appropriate. Because the ECMO circuit included the heat exchanger, the
changing of temperature alone was not regarded as a sign of infection.
When infection was clinically suspected, an empiric wide-spectrum antibi-
otic therapy was administered immediately after collecting samples for mi-
crobiology. Once the causative pathogen was known and the antibiogram
was available, the antibiotic therapy was pathogen-tailored. The oxygena-
tor and cannulae were not changed after infection identification.
Parameters of Interest
Two separate blood samples were collected each morning to determine
CRP and PCT values, and only 1 value of CRP and of PCTwas analyzed per
day. PCT values were detected with the Elecsys BRAHMS PCT assay
(Brahms, Berlin, Germany), and CRP was determined by a turbidimetric
immunoassay (Siemens Healthcare Diagnostics Inc, Deerfield, Ill).
Statistical Analysis
Analysis of the parameters of interest (CRP and PCT) was performed on
the values measured once daily during the ECMO run and not on baseline
values. Categoric variables are expressed as numbers and percentages,gery c June 2012
TABLE 1. Study population baseline characteristics
Parameter
Total VV ECMO VA ECMO P
value(n ¼ 27) (n ¼ 11) (n ¼ 16)
Age, y 54.9  11.3 49.6  13.1 58.6  8.6 .01
Gender (male), n 20 (74.1%) 6 (54.6%) 14 (87.5%) .07
Weight, kg 73.2  13.6 73.1  17.2 73.3  11.1 .7
Height, cm 170.2  6.8 168.5  9.3 171.2  43.5 .5
BMI 25.5  3.4 26.3  3.5 25.0  3.4 .3
BSA 1.9  0.2 1.9  0.2 1.9  0.2 .9
Medical
hospitalization, n
13 (48.2%) 7 (63.6%) 6 (37.5%) .8
Elective surgery
hospitalization, n
12 (44.4%) 3 (27.3%) 9 (56.3%) .08
Nonelective surgery
hospitalization, n
2 (7.4%) 1 (9.1%) 1 (6.3%) .9
APACHE II score 14.9  7.1 12.1  4.6 16.8  8.0 .1
SOFA score 8.0  3.3 7.8  4.0 8.2  2.8 .3
ECMO, Extracorporeal membrane oxygenation; BMI, body mass index; BSA, body
surface area; APACHE II, Acute Physiology And Chronic Health Evaluation II;
SOFA, Sequential Organ Failure Assessment.
Pieri et al Evolving Technology/Basic Sciencewhereas continuous variables are shown as mean standard deviation or as
median and interquartile range if the standard deviation is larger than the
mean in magnitude.
For group comparisons, binomial test was used for dichotomous vari-
ables, whereas Mann–Whitney U test or Mood’s median test was per-
formed for assay mean or median difference, respectively. Moreover, the
Spearman rank-order correlation coefficient was used to compare PCT
and CRP variation.
The relation among PCT, CRP, infection, and other parameters under
study was analyzed with a generalized estimating equations model, taking
into account correlations within patients’ measurements, assuming the
same correlation between any 2 elements of a cluster (exchangeable corre-
lation matrix).5,6
Receiver operating characteristic (ROC) analysis7 was used to identify
the most appropriate cutoff values for the diagnosis of infection. The per-
formance of the diagnostic tests was evaluated with the nonparametric
method of DeLong and colleagues,8 assessing the difference from the non-
discriminating ROC curve (area under the curve ¼ 0.5). Sensitivity (SE),
specificity (SP), positive predictive value (PPV), negative predictive value
(NPV), and misclassification rate were assessed with reference to PCTandTABLE 2. Study population data
Parameter Total (n ¼ 27) V
CRP, mg/L 200.7 (78.4–240.9)
CRP maximum value registered, d 2 (1–4)
PCT, ng/mL 3.5 (0.6–15.1)
PCT maximum value registered, d 2 (1–4)
WBC, 109/L 14.2 (9.9–17.9)
WBC maximum value registered, d 3 (1–6)
PC,% 48.6 (42.1–72.3)
PC maximum value registered, d 2 (1–6)
Lactates, mmol/L 4.22 (2.36–6.73)
ECMO, d 6.6  3.8
Hospital stay, d 16 (10–51)
ICU stay, d 15 (7–32)
Death on ECMO, n 8 (29.6%)
Infection, n 13 (48.1%)
ECMO, Extracorporeal membrane oxygenation; CRP, C-reactive protein; PCT, procalcito
The Journal of Thoracic and CarCRP cutoff values, and their 95% CI was calculated with binomial approx-
imation. Calculation of SE, SP, PPV, and NPV is referred to in the text as
‘‘accuracy evaluation.’’ To set the false-negative count to zero and to con-
firm a negative test result, both tests were assessed in parallel with ‘‘the OR
rule’’ (positive diagnosis if either test is positive and negative diagnosis if
both tests are negative).9 This resulted in the creation of a new variable that
we called the ‘‘PCT and CRP combined assay.’’
Because of the presence of a conditional dependence between the 2 di-
agnostic tests, we calculated the covariance of SE and SP and corrected the
estimate of the diagnostic performance accordingly.10 Data were analyzed
with SAS 2002–2008 software (release 9.2 by SAS Institute Inc, Cary, NC).RESULTS
The study population baseline characteristics are shown
in Table 1, and the study population data are shown in
Table 2. The mean number of days on ECMO support
was 6.6  3.8, specifically 7.0  2.7 days in VV cases
and 6.4  4.5 days in VA cases.
Eight patients (29.6%) died on ECMO, and no significant
difference in mortality between the VV ECMO and VA
ECMO groups was observed. The median ICU stay was
15 (7–32) days, and the median hospital stay was 16 (10–
51) days, with no statistically significant difference between
the groups.
No patient had hemolysis. Thirteen patients (48%) had
bacterial or fungal infection: In 7 patients (26%), infection
was acquired while on extracorporeal support, and the other
6 patients (22%) had preexisting infection. An overview of
infections is shown in Table 3.
We observed 3 episodes of bloodstream infection and 10
infections with negative blood cultures. Among patients
without bloodstream infection, we reported 8 pneumonias
(7 episodes with positive tracheal specimen and 1 case
with positive bronchoalveolar lavage) and 2 episodes of in-
fection with negative microbiological investigations.
Twelve different pathogens were isolated in a total of 13
isolates: gram-negative bacteria were the most common
(54%), followed by fungi (23%) and gram-positiveV ECMO (n ¼ 11) VA ECMO (n ¼ 16) P value
216.9 (142.3–264.0) 111.3 (76.0–206.4) .03
2 (1–3) 3 (1–4) .6
4.2 (0.3–13.4) 3.1 (0.9–21.0) .9
2 (0–5) 1.5 (1–3.5) .2
11.5 (5.3–17.4) 14,6 (11.4–17.9) .2
4 (3–7) 2 (0.5–3.5) .1
47.9 (47.0–64.7) 48.6 (42.1–72.3) .9
5 (2–7) 2 (0.5–5) .6
2.66 (1.9–7.8) 4.5 (2.9–6.1) .5
7.0  2.7 6.4  4.5 .4
17 (11–41) 15.5 (7–52) .06
15 (10–32) 15.5 (6–29.5) .07
4 (36.4%) 4 (25.0%) .9
5 (45.5%) 8 (50%) .8
nin; WBC, white blood cell; PC, protein C; ICU, intensive care unit.
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TABLE 3. Infection overview
Patient
Extracorporeal
support
Type of
infection* Pathogen
1 VV ECMO Pneumonia Acinetobacter baumannii
2 VV ECMO Bloodstream
Bloodstream
Candida albicans
Corynebacterium
minutissimum
3 VV ECMO Pneumonia Stenotrophomonas
maltophilia
4 VV ECMO Pneumonia Enterobacter aerogenes
5 VV ECMO Pneumonia No pathogen isolated
6 VA ECMO Pneumonia Serratia marcescens
7 VA ECMO Pneumonia Aspergillus fumigatus
8 VA ECMO Pneumoniaþ
bloodstream
Escherichia coli
Pneumonia Klebsiella pneumoniae
9 VA ECMO Bloodstream Candida albicans
10 VA ECMO Pneumonia MRSA
11 VA ECMO Pneumonia Haemophilus influenzae
12 VA ECMO Cholecystitis No pathogen isolated
13 VA ECMO Pneumonia Staphylococcus aureus
MRSA, Methicillin-resistant Staphylococcus aureus. *According to Centers for
Disease Control and Prevention criteria for specific types of health care–associated
infection.
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Smicroorganisms (23%). The most frequently isolated path-
ogen was a fungus: Candida albicans was isolated in 2 ep-
isodes. Moreover, Staphylococcus aureus was the most
frequent isolated gram-positive bacterium (67%).
PCT mean values were associated with the ECMO con-
figuration (regression coefficient ¼9.327, P ¼ .047), ad-
justed for CRP value (regression coefficient ¼ 0.042,
P ¼ .03). Therefore, a stratified analysis according to the
ECMO configuration was mandatory to detect the optimal
cutoff for the diagnosis of infection. On the contrary, we
found that CRP mean values were significantly associated
with age (regression coefficient ¼5.075, P ¼ .002) and
gender (regression coefficient ¼90.752, P ¼ .01) but not
with the ECMO configuration. Thus, a single cutoff value
for CRP was appropriate for both the VV ECMO and VA
ECMO groups. In addition, we found a significant positive
correlation between PCT and CRP (Spearman’s rank corre-
lation coefficient ¼ 0.38, P<.001).
The ROC curve of PCT was not significantly different
from the nondiscriminating ROC curve (P¼ .07). However,
if we distinguish between the 2 types of ECMO configura-
tion, we found that PCT is a reliable biomarker for the diag-
nosis of infection in patients undergoing VA ECMO (area
under the curve, 0.681; 95% CI, 0.551–0.811; P ¼ .0062)
(Figure E1) but not in patients receiving VV ECMO
(P ¼ .14). On the other hand, the ROC analysis confirmed
a good accuracy of CRP in the discrimination of patients
with and without infection in all ECMO cases (area under
the curve, 0.707; 95% CI, 0.623–0.791; P < .001)
(Figure E2).1414 The Journal of Thoracic and Cardiovascular SurIn the light of these data, we focused only on patients re-
ceiving VA ECMO. We performed an accuracy evaluation
of PCT as a possible diagnostic test for infection and com-
pared it with CRP. We confirmed a good accuracy of the
PCT diagnostic test with 1.89 ng/mL as the optimal cutoff
point (SE ¼ 87.8% [95% CI, 78.6–96.9], SP ¼ 50%
[95% CI, 33.7–66.3], PPV ¼ 70.5% [95% CI, 59–81.9],
NPV ¼ 75% [95% CI, 57.7–92.3], misclassification
rate¼ 28.2% [95%CI, 18.7–37.8]) and the CRP diagnostic
test with 97.70 mg/L as the cutoff (SE ¼ 85.3% [95% CI,
76.9–93.7], SP ¼ 41.6% [95% CI, 30.6–52.6],
PPV ¼ 56.3% [95% CI, 46.7–65.9], NPV ¼ 76.2%
[95% CI, 63.3–89.1], misclassification rate ¼ 37.9%
[95% CI, 30–45.8]).
The probability of a negative test result in infection de-
tection, when performing both diagnostic tests in parallel,
decreased to 0.018 (SE ¼ 98.2%, SP ¼ 20.8%). Because
of the presence of a conditional dependence between PCT
and CRP, however, the estimate of the diagnostic perfor-
mance of the 2 tests in parallel was adjusted according to
the SE and SP covariance of 0.110 and 0.051, respectively
(SE ¼ 87.2%, SP ¼ 25.9%).
Four variables were identified as statistically significant
predictors of infection: parallel test result, that is, the
‘‘PCT and CRP combined assay’’ (odds ratio [OR] ¼
1.184; 95% confidence interval [CI], 1.073–1.307,
P < .001), age (OR ¼ 0.980; 95% CI, 0.972–0.988,
P<.001), presence of infection before ECMO implantation
(OR¼ 1.782; 95%CI, 1.462–2.171,P<.001), and duration
of ECMO support (OR ¼ 1.056; 95% CI, 1.029–1.084,
P<.001).
DISCUSSION
This is the first study to address the role of traditional
and emerging biomarkers in the diagnosis of infection in
patients undergoing ECMO. The most interesting result
is the creation of a new test, the ‘‘PCT and CRP combined
assay,’’ which was proved to be a statistically significant
predictor of infection in patients receiving VA ECMO,
along with younger age, presence of infection before the
ECMO support, and longer duration of the ECMO support.
It is a promising finding, especially because infection in
patients undergoing extracorporeal support is a major
complication.
Infection rates and causal organisms of 20,741 patients
receiving ECMO were recently reported in a query con-
ducted on the Extracorporeal Life Support Organization
registry on behalf of the Extracorporeal Life Support Orga-
nization Task Force on Infections and ECMO.11 Our study
confirmed similar results, because we observed that bacte-
rial or fungal infection developed in approximately half of
the patients receiving ECMO. Of note, such infections
were not always correlated to the cannulation site; rather,
we observedmainly bloodstream infections and pneumonia.gery c June 2012
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SA recent study by Sun and colleagues12 reported an
ECMO-related infection rate of 13.5% in a series of 334 pa-
tients. Because the aim of our study was to establish the role
of serum biomarkers in the diagnosis of infection in patients
on ECMO, we studied the day-by-day changes in biomarker
values in patients with or without infection during ECMO
support regardless of whether the infection was preexisting.
Among the 13 patients with infection of our study, only 7
(26%) had ECMO-related infection. Furthermore, Bizzarro
and colleagues11 reported an infection rate of 20.9% in
2298 adult patients, which is similar to the infection rate
we observed in our sample.
However, few patients on ECMO are 100% infection
free. Even at the time of cannulation, it is difficult to define
whether a patient is truly infection free, because ECMO is
often used in patients with ARDS or who have undergone
elective or nonelective surgery.
Moreover, ECMO is frequently used as a bridge to other
therapies, such as heart or lung transplantation and long-
term ventricular assist device implantation. However, the
presence of infection jeopardizes patients’ candidacy to re-
ceive these therapeutic options. For this reason, reliable
tools for the diagnosis of infection are strongly needed, irre-
spective of the speculations concerning whether the infec-
tion can be defined as related to ECMO or not.
Traditional inflammatory marker assays (eg, CRP and
white blood cell count) are often distorted in such pa-
tients by the presence of non-septic SIRS. Because the
extracorporeal circuit is a foreign body in constant con-
tact with the patient’s blood, it triggers the activation
of defense mechanisms, resulting in a marked inflamma-
tory response.
In regard to PCT, patients with established sepsis diagno-
sis generally have higher serum levels than those with SIRS
only, and patients with severe sepsis and septic shock are re-
ported to have the highest levels.13,14 However, no study
previously analyzed PCT as an infection marker in patients
undergoing extracorporeal support. Few pioneering studies
described PCT kinetics in cardiopulmonary bypass, which
is routinely used in cardiac surgery.
Significantly increased PCT values are not observed in
the absence of postoperative complications,15 and PCT
levels in patients with infection are generally higher than
in patients with noninfectious complications.16 Neverthe-
less, it is difficult to recommend cutoff points.
The presence of H1N1 influenza A pneumonia in 7 of the
27 patients is not a limitation of the study, because PCT is
supposed to have low or undetectable levels in the case of
viral infection.17-19 Furthermore, some studies also
successfully demonstrated that PCT can assist in bacterial
infection diagnosis and tailored antibiotic use in patients
with H1N1 pneumonia.20,21
In regard to the other acute-phase reactants, a record of
increased PCT values must be interpreted cautiously. ThereThe Journal of Thoracic and Caris an overlap between SIRS and sepsis, and many situations
other than infection may trigger PCT synthesis and release,
including inhalational injury, burn injury, pancreatitis, me-
chanical trauma, extensive surgery (eg, aortic, cardiac, co-
lonic),16,22,23 and cardiogenic shock.24 We acknowledge
that many of these conditions were present in our study pop-
ulation and may have partly influenced the PCT values and
our results. Of note, several studies available in the litera-
ture concluded that a combination of PCT and CRP would
provide the most useful information in the diagnosis of
infection.21,22
Our study demonstrated that a concomitant PCTand CRP
assay is useful in the critical care setting of patients under-
going VA ECMO, because PCT and CRP reach a strong SE
(87.2%) when performed together, even with a low SP
(25.9%). Furthermore, because the PCTand CRP combined
assay was proven to be a statistically significant predictor of
infection, its usewould be of benefit to clinical routine prac-
tice. The other 3 predictors of infection that we found (age,
presence of infection before ECMO implantation, and dura-
tion of ECMO support) cannot assist the medical attending
team in day-to-day clinical decision-making. We showed
that the PCT and CRP combined assay can aid in the diag-
nosis of infection in patients with VA ECMO, and further
study will help us to analyze its role in the management
of antibiotic therapy.
The low SP of the PCT and CRP combined assay is to be
interpreted in light of the fact that we chose to privilege
sensitivity to have a high NPV and to exclude the presence
of infection as certain as possible if the test was negative.
This observation may justify sparing antibiotic therapy for
patients with a negative PCT and CRP combined assay
test result, with a low error rate.
Our study also shows that PCT is not a reliable marker of
infection in patients undergoing VV ECMO. Although the
number of patients studied is small, we can argue that be-
cause the circuit is the same for VV ECMO and VA
ECMO, such difference should be attributed to the patients.
In particular, almost every patient with ARDS requiring VV
ECMO had primary lung infection in contrast with the pri-
mary cardiac failure, which was typical of patients sup-
ported with VA ECMO. This observation paves the way
for new studies to characterize the different categories of
patients requiring ECMO treatment according to disease
and comorbidity.
Study Limitations
The study has 4 important limitations. First, the small
number of patients does not allow strong and general con-
clusions, even if the results are impressive. Second, distin-
guishing between SIRS and sepsis in patients on ECMO
is an important problem. Nevertheless, these data would
suggest no change in the clinical management of these pa-
tients, because the overlap among cardiogenic shock,diovascular Surgery c Volume 143, Number 6 1415
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SSIRS, ECMO itself, and sepsis will always be part of the
clinical scenario. Third, in a study conducted on 194 pa-
tients with community-acquired infection, Gaini and col-
leagues25 found that interleukin 6, lipopolysaccharide
binding protein, and CRP performed best in distinguishing
between SIRS and sepsis, whereas PCT performed best in
distinguishing between sepsis and severe sepsis.25 Because
the patients included in the study had community-acquired
infection instead of nosocomial infections and were not ad-
mitted to an ICU, it would be of interest to perform a similar
study in the setting of critical care medicine. However, the
transferability of this knowledge in the clinical application
of ECMO is hard. Fourth, we were unable to identify a new
test for the diagnosis of infection in patients undergoing VV
ECMO, and further studies on this topic are strongly
warranted.
CONCLUSIONS
We suggest a concomitant PCT and CRP assay with def-
inite cutoff values as a new test to identify infection in pa-
tients undergoing VA ECMO. PCT routine dosing may be
useful for infection diagnosis in patients requiring ECMO
and would lead to a more rational and appropriate clinical
management of these high-risk patients.
The authors thank Turla Otello Giancarlo and Motta Andrea,
MD, for the support in data collection and analysis.
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FIGURE E1. ROC curve of PCT in patients treated with VA ECMO.
ROC, Receiver operating characteristic.
FIGUREE2. ROC curve of CRP in all patients treated with ECMO. ROC,
Receiver operating characteristic.
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